NovaRay Medical, Inc. was founded in 2005 to develop and commercialize a revolutionary digital x-ray technology for medical imaging. The company acquired substantially all the assets, including the intellectual property, of NexRay, Inc., which had invested approximately $80 million in the development of a real-time, low-dose tomographic imaging system applicable for cardiac catheterization and a variety of clinical applications.

NovaRay’s first product, the ScanCathTM system, addresses the $1.1 billion per year cardiac catheterization market, by providing enhanced image quality, real-time multi-slice tomography, a dramatic reduction in radiation exposure for both physicians and patients, and open patient access. The technology, which is protected by 23 issued U.S. patents, has been clinically validated at the University of Wisconsin-Madison, and the company has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA).

The company is headquartered in Newark, CA.